Please login to the form below

Not currently logged in
Email:
Password:

atomoxetine

This page shows the latest atomoxetine news and features for those working in and with pharma, biotech and healthcare.

Shire launches long-acting ADHD drug Intuniv in UK

Shire launches long-acting ADHD drug Intuniv in UK

It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who

Latest news

  • Lilly feels effects of Cymbalta competition Lilly feels effects of Cymbalta competition

    to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

  • Lilly’s Strattera wins new adult ADHD licence in UK Lilly’s Strattera wins new adult ADHD licence in UK

    The Medicines and Healthcare Products Regulatory Agency (MHRA) granted authorisation to expand the indication of Strattera (atomoxetine) to initiate treatment of ADHD in adults, where pre-existing symptoms during childhood can

  • Therapy focus: ADHD

    The most commonly prescribed non-stimulant is atomoxetine. It is believed to work by increasing the amount of noradrenaline (one of the brain's chemical messengers), which helps manage the symptoms ... The most common side effects of atomoxetine are

  • Lilly's Strattera patent upheld in US

    The US court of appeals has upheld the validity of Eli Lilly &Company's patent for attention deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine). ... Companies looking to capitalise on the loss of patent with their own versions of

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics